{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:50:34Z","timestamp":1792734634992,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T00:00:00Z","timestamp":1501891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["P30CA022453"],"award-info":[{"award-number":["P30CA022453"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10549-017-4435-x","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T07:16:49Z","timestamp":1501917409000},"page":"407-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer"],"prefix":"10.1007","volume":"166","author":[{"given":"Cecilia L.","family":"Speyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam A.","family":"Bukhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waris S.","family":"Jafry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeshna","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-6699","authenticated-orcid":false,"given":"David H.","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,5]]},"reference":[{"key":"4435_CR1","unstructured":"American Cancer Society I: breast cancer facts & figures (2015\u20132016). American Cancer Society, Inc, Atlanta"},{"key":"4435_CR2","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1041.S2-001","author":"K Aysola","year":"2013","unstructured":"Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ et al (2013) Triple negative breast cancer\u2014an overview. Hereditary Genet. doi:\n                    10.4172\/2161-1041.S2-001","journal-title":"Hereditary Genet"},{"issue":"15 Pt 1","key":"4435_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4435_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.3390\/cancers6042187","volume":"6","author":"P Mancini","year":"2014","unstructured":"Mancini P, Angeloni A, Risi E, Orsi E, Mezi S (2014) Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers 6(4):2187\u20132223","journal-title":"Cancers"},{"issue":"3","key":"4435_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1245\/s10434-014-4279-0","volume":"22","author":"LA Newman","year":"2015","unstructured":"Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA (2015) The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol 22(3):874\u2013882","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4435_CR6","doi-asserted-by":"publisher","first-page":"e81126","DOI":"10.1371\/journal.pone.0081126","volume":"9","author":"M Banda","year":"2014","unstructured":"Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR et al (2014) Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS ONE 9(1):e81126","journal-title":"PLoS ONE"},{"issue":"2","key":"4435_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-011-1624-x","volume":"132","author":"CL Speyer","year":"2012","unstructured":"Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH (2012) Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 132(2):565\u2013573","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4435_CR8","doi-asserted-by":"publisher","first-page":"e88830","DOI":"10.1371\/journal.pone.0088830","volume":"9","author":"CL Speyer","year":"2014","unstructured":"Speyer CL, Hachem AH, Assi AA, Johnson JS, DeVries JA, Gorski DH (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS ONE 9(3):e88830","journal-title":"PLoS ONE"},{"issue":"1","key":"4435_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","volume":"17","author":"MC Bellingham","year":"2011","unstructured":"Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17(1):4\u201331","journal-title":"CNS Neurosci Ther"},{"issue":"9030","key":"4435_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0140-6736(96)03181-9","volume":"348","author":"J Wokke","year":"1996","unstructured":"Wokke J (1996) Riluzole. Lancet 348(9030):795\u2013799","journal-title":"Lancet"},{"issue":"7","key":"4435_CR11","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1158\/1078-0432.CCR-10-1276","volume":"17","author":"AJ Khan","year":"2011","unstructured":"Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG (2011) Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 17(7):1807\u20131814","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4435_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/pcmr.12207","volume":"27","author":"BA Wall","year":"2014","unstructured":"Wall BA, Wangari-Talbot J, Shin SS, Schiff D, Sierra J, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S (2014) Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res 27(2):263\u2013274","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"4435_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-016-3816-x","volume":"157","author":"CL Speyer","year":"2016","unstructured":"Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM, Gorski DH (2016) Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. Breast Cancer Res Treat 157(2):217\u2013228","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"4435_CR14","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/jid.2010.126","volume":"130","author":"MN Le","year":"2010","unstructured":"Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA, Goydos JS (2010) The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 130(9):2240\u20132249","journal-title":"J Invest Dermatol"},{"issue":"4","key":"4435_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1006\/nbdi.2000.0297","volume":"7","author":"KM Noh","year":"2000","unstructured":"Noh KM, Hwang JY, Shin HC, Koh JY (2000) A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C. Neurobiol Dis 7(4):375\u2013383","journal-title":"Neurobiol Dis"},{"issue":"1","key":"4435_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tranon.2014.11.001","volume":"8","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Niglio SA, Salehomoum N, Chan JL, Jeong BS, Wen Y, Li J, Fukui J, Chen S, Shin SS et al (2015) Targeting glutamatergic signaling and the PI3 kinase pathway to halt melanoma progression. Transl Oncol 8(1):1\u20139","journal-title":"Transl Oncol"},{"issue":"11","key":"4435_CR17","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-08-3303","volume":"15","author":"D Yip","year":"2009","unstructured":"Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, Kempf J, Shih WJ, Chen S, Goydos JS (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15(11):3896\u20133902","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4435_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253\u2013265","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4435_CR19","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750\u20132767","journal-title":"J Clin Invest"},{"issue":"19","key":"4435_CR20","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","volume":"19","author":"H Masuda","year":"2013","unstructured":"Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19(19):5533\u20135540","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4435_CR21","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6):285\u2013290","journal-title":"Arzneimittelforschung"},{"key":"4435_CR22","unstructured":"Speyer CL, Gorski DH (2017) Genome-wide analysis of differential gene expression in MDA-MB-231 cells after overnight treatment with riluzole. GEO Accession: GSE96653"},{"key":"4435_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1548-5315(11)70394-1","volume":"7","author":"DW Cleere","year":"2010","unstructured":"Cleere DW (2010) Triple-negative breast cancer: a clinical update. Commun Oncol 7:203\u2013211","journal-title":"Commun Oncol"},{"issue":"1","key":"4435_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.virol.2008.12.041","volume":"386","author":"A Achour","year":"2009","unstructured":"Achour A, M\u2019Bika JP, Biquard JM (2009) Enhanced endogenous type I interferon cell-driven survival and inhibition of spontaneous apoptosis by Riluzole. Virology 386(1):160\u2013167","journal-title":"Virology"},{"issue":"30","key":"4435_CR25","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1038\/sj.onc.1204537","volume":"20","author":"IM Berquin","year":"2001","unstructured":"Berquin IM, Dziubinski ML, Nolan GP, Ethier SP (2001) A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin. Oncogene 20(30):4019\u20134028","journal-title":"Oncogene"},{"issue":"5","key":"4435_CR26","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0360-3016(00)01358-4","volume":"48","author":"GS Rao","year":"2000","unstructured":"Rao GS, Murray S, Ethier SP (2000) Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48(5):1519\u20131528","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"4435_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1365-2559.2011.04160.x","volume":"27","author":"V Martin","year":"2012","unstructured":"Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L, Frattini M (2012) Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 27(6):785\u2013792","journal-title":"Histol Histopathol"},{"issue":"8","key":"4435_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1541-7786.MCR-06-0427","volume":"5","author":"KL Streicher","year":"2007","unstructured":"Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP (2007) Activation of a nuclear factor kappaB\/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res 5(8):847\u2013861","journal-title":"Mol Cancer Res"},{"issue":"18","key":"4435_CR29","doi-asserted-by":"publisher","first-page":"7564","DOI":"10.1073\/pnas.0702507104","volume":"104","author":"LH Saal","year":"2007","unstructured":"Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmstrom P, Memeo L et al (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104(18):7564\u20137569","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"4435_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.molonc.2014.10.006","volume":"9","author":"CS Kappler","year":"2015","unstructured":"Kappler CS, Guest ST, Irish JC, Garrett-Mayer E, Kratche Z, Wilson RC, Ethier SP (2015) Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer. Mol Oncol 9(2):527\u2013543","journal-title":"Mol Oncol"},{"issue":"8","key":"4435_CR31","doi-asserted-by":"publisher","first-page":"e3065","DOI":"10.1371\/journal.pone.0003065","volume":"3","author":"QB She","year":"2008","unstructured":"She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N (2008) Breast tumor cells with PI3\u00a0K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3(8):e3065","journal-title":"PLoS ONE"},{"issue":"Pt 3","key":"4435_CR32","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1042\/bj3330757","volume":"333","author":"NJ Hellyer","year":"1998","unstructured":"Hellyer NJ, Cheng K, Koland JG (1998) ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 333(Pt 3):757\u2013763","journal-title":"Biochem J"},{"issue":"15","key":"4435_CR33","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE (2003) The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: Erbb2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100(15):8933\u20138938","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4435_CR34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1535-7163.MCT-05-0013","volume":"4","author":"JR Stewart","year":"2005","unstructured":"Stewart JR, O\u2019Brian CA (2005) Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol Cancer Ther 4(5):726\u2013732","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4435_CR35","first-page":"2195","volume":"29","author":"K Akamatsu","year":"2009","unstructured":"Akamatsu K, Shibata MA, Ito Y, Sohma Y, Azuma H, Otsuki Y (2009) Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress. Anticancer Res 29(6):2195\u20132204","journal-title":"Anticancer Res"},{"issue":"6","key":"4435_CR36","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1074\/jbc.M512167200","volume":"281","author":"L Li","year":"2006","unstructured":"Li L, Sampat K, Hu N, Zakari J, Yuspa SH (2006) Protein kinase C negatively regulates Akt activity and modifies UVC-induced apoptosis in mouse keratinocytes. J Biol Chem 281(6):3237\u20133243","journal-title":"J Biol Chem"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4435-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4435-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4435-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:01:19Z","timestamp":1589720479000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4435-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,5]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4435"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4435-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,5]]},"assertion":[{"value":"12 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. Animal studies were approved by the local Institutional Animal Care and Use Committee (IACUC) at Wayne State University which is structured and operated in accordance with NIH\u2019s Office of Laboratory Animal Welfare (OLAW) <i>Public Health Service Policy on Humane Care and Use of Laboratory Animals<\/i> (Public Health Service NIH Assurance Number D16-00198).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}